Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $22.50.

DCTH has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Delcath Systems in a report on Friday, January 9th. Evercore set a $27.00 target price on Delcath Systems in a research note on Thursday. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a research note on Monday, December 29th. Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a report on Saturday. Finally, BTIG Research decreased their price objective on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday.

Key Headlines Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Company reported Q4 and full‑year 2025 results with Q4 revenue of $20.7M and full‑year revenue of $85.2M; EPS of ($0.05) beat consensus by $0.01 — evidence of improving commercial execution. BusinessWire Release
• Positive Sentiment: Management is targeting at least $100M in revenue for 2026 and plans to expand to ~40 treatment centers, signaling a clear growth roadmap and potential material revenue upside if execution continues. Seeking Alpha
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to ~$100.0M (effectively in line with consensus ~100.1M); guidance confirms the growth target but leaves little upside vs. street estimates absent faster center rollout or higher per‑center revenue. MarketBeat Earnings
• Neutral Sentiment: BTIG cut its price target from $23 to $19 but kept a “buy” rating—still implying substantial upside from current levels, though the downgrade signals more conservative near‑term expectations from at least one sell‑side shop. Street Insider

Institutional Investors Weigh In On Delcath Systems

Several hedge funds have recently bought and sold shares of DCTH. Nantahala Capital Management LLC acquired a new position in shares of Delcath Systems in the third quarter valued at approximately $7,164,000. Marshall Wace LLP bought a new stake in Delcath Systems in the 2nd quarter valued at $6,572,000. Divisadero Street Capital Management LP bought a new stake in Delcath Systems in the 3rd quarter valued at $5,119,000. Rosalind Advisors Inc. increased its position in Delcath Systems by 13.8% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock worth $44,885,000 after buying an additional 400,000 shares during the period. Finally, Geode Capital Management LLC increased its position in Delcath Systems by 128.1% during the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company’s stock worth $9,565,000 after buying an additional 394,902 shares during the period. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Trading Down 1.1%

NASDAQ:DCTH opened at $8.90 on Monday. The stock has a market capitalization of $309.28 million, a PE ratio of 127.14 and a beta of 0.38. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $18.23. The firm has a fifty day simple moving average of $9.98 and a 200 day simple moving average of $10.19.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The firm had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $20.35 million. Delcath Systems had a net margin of 3.17% and a return on equity of 2.70%. On average, equities analysts predict that Delcath Systems will post -0.79 earnings per share for the current fiscal year.

Delcath Systems declared that its Board of Directors has approved a share buyback plan on Thursday, November 20th that authorizes the company to repurchase $25.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 8.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.